Generated: May 29, 2017
|Title:||Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation|
|Abstract:||The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps: a--initiate beta-blockers treatment at a low dose; b--performing a electrocardiogram (ECG) verification of good tolerability; c--increase of beta-blockers dose only if results in step b) are satisfying.|
|Inventor(s):||Radzik; Davide (Paris, FR)|
|Assignee:||Sanofi (Paris, FR)|
Patent Claim Types:|
see list of patent claims
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
Sanofi Aventis Us
|TABLET;ORAL||022425-001||Jul 1, 2009||RX||Yes||Yes||8,602,215||► Subscribe||MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.